Journal Article Summary
The article investigates the effectiveness of infliximab in treating chronic non-infectious uveitis in children who have not responded to previous biologic therapies, particularly adalimumab. This topic is significant because chronic uveitis can lead to serious vision problems in children, and there is limited guidance on how to manage cases that do not improve with standard treatments. Understanding whether infliximab can provide relief for these patients is crucial for improving their quality of life and preventing long-term complications.
The study involved a review of medical records from pediatric patients at Bristol Eye Hospital who were switched to infliximab due to inadequate control of their uveitis. Two groups were analyzed: one group switched from adalimumab and another from different biologic treatments. The results showed a significant reduction in inflammation in the anterior chamber of the eye after 6 months and 24 months of infliximab treatment, particularly in the group that switched from adalimumab. However, the small size of the second group limited the strength of the findings for those patients.
Despite the promising results, the study has limitations, including its retrospective design and the lack of control groups, which may introduce bias. Additionally, not all patients had their anti-infliximab antibodies measured, which could affect treatment outcomes. Patients and caregivers should discuss these findings with healthcare professionals to understand the potential benefits and risks of switching to infliximab, especially in the context of ongoing treatment for uveitis and any other underlying conditions.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Kreps E. O., Epps S. J., Consejo A., Dick A. D., Guly C. M., Ramanan A. V.. Infliximab in chronic non-infectious paediatric uveitis refractory to previous biologic therapy. Eye 2023. DOI: 10.1038/s41433-023-02795-3. PMID: 37848676. PMCID: PMC10965986.
Featured Pill Pals Product
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira
Adalimumab-ADAZ 40 MG / 0.4 ML Auto Injector x 2 Syringes --- Sandoz Brand --- Bioequivalent to Humira is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription may be required.
